MIRA PHARMACEUTICALS INC

For the period ended Mar 31, 2024. Filed May 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 13, 2024

MIRA$0.57+5.6%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 6. Exhibits

Number	Description
3.1	Third Amended and Restated Articles of Incorporation of MIRA Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 of the Company’s Registration Statement on Form S-1 (File No. 333-273024) filed with the SEC on June 29, 2023).
3.2	Amended and Restated Bylaws of MIRA Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.3 of the Company’s Registration Statement on Form S-1, as amended (File No. 333-273024) filed with the SEC on July 28, 2023).
31.1*	Certification of Chief Executive Officer Pursuant to Sarbanes-Oxley Section 302
31.2*	Certification of Interim Chief Financial Officer Pursuant to Sarbanes-Oxley Section 302
32.1**	Certification Pursuant To 18 U.S.C. Section 1350 (*)
32.2**	Certification Pursuant To 18 U.S.C. Section 1350 (*)
101.ins*	Inline XBRL Instance Document
101.sch*	Inline XBRL Taxonomy Extension Schema Document
101.cal*	Inline XBRL Taxonomy Calculation Linkbase Document
101.def*	Inline XBRL Taxonomy Definition Linkbase Document
101.lab*	Inline XBRL Taxonomy Label Linkbase Document
101.pre*	Inline XBRL Taxonomy Presentation Linkbase Document
104*	The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in Inline XBRL.
*	Filed herewith.
**	Furnished herewith.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.